Clearing Viral Concerns in Animal-Derived Biomaterials - Viruses in animal-derived starting materials could contaminate biopharmaceutical final product. A rigorous testing strategy and removal methods

ADVERTISEMENT

Clearing Viral Concerns in Animal-Derived Biomaterials
Viruses in animal-derived starting materials could contaminate biopharmaceutical final product. A rigorous testing strategy and removal methods are reviewed.


BioPharm International
Volume 26, Issue 8, pp. 42-45


Kate Smith
There is a possibility that viruses could be present in animal-derived starting materials used in biopharmaceutical production and, therefore, potentially contaminate the final product. Because of the potential risk to the end user, it is crucial to approach the safety of these therapeutic products through a rigorous and systematic testing strategy. Kate Smith, principal scientist, development services at BioReliance offers insights on the tests required to check for the presence of these contaminants and how to remove the contaminants that are present in final products using chemical inactivation or processes such as chromatography and nanofiltration.

Material Risks
Biopharmaceutical manufacturing processes frequently rely on starting materials derived from mammalian sources. The level of risks that these materials present are contingent upon the nature of the starting material, mainly, whether they come from human or animal sources.

One example of human-derived material is plasma. Despite the screening of blood donations, when a product is being manufactured from human plasma, there is potential for contamination by pathogens such as hepatitis and human immunodeficiency virus (HIV).

Additionally, many biological drugs are manufactured in Chinese hamster ovary (CHO) or murine cell lines. With these cell lines, it is rare for viruses to be absent. While these materials are well characterized and screened for viruses in advance, the cells commonly contain endogenous viral contamination, typically in the form of a retrovirus. This virus is detected and quantified using transmission electron microscopy as part of the bulk-harvest testing.

This risk is not limited to biopharmaceutical materials. Even products falling into the medical-device category can be affected, such as collagen preparations. Collagen is derived from animal tissues; therefore, there is a high probability that a viral pathogen may be present.

Viruses may also enter the process or product by adventitious means. For instance, a contaminated raw material may be introduced into the process, or viral contamination could have entered the cell culture from a human operator.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here